ACADIA Pharmaceuticals Inc.

BMV:ACAD * Stock Report

Market Cap: Mex$68.8b

ACADIA Pharmaceuticals Management

Management criteria checks 2/4

ACADIA Pharmaceuticals' CEO is Steve Davis, appointed in Sep 2015, has a tenure of 8.08 years. total yearly compensation is $14.03M, comprised of 5.9% salary and 94.1% bonuses, including company stock and options. directly owns 0.054% of the company’s shares, worth MX$37.43M. The average tenure of the management team and the board of directors is 2 years and 8 years respectively.

Key information

Steve Davis

Chief executive officer

US$14.0m

Total compensation

CEO salary percentage5.9%
CEO tenure8.1yrs
CEO ownership0.05%
Management average tenure2yrs
Board average tenure8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Steve Davis's remuneration changed compared to ACADIA Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$111m

Mar 31 2023n/an/a

-US$146m

Dec 31 2022US$14mUS$822k

-US$216m

Sep 30 2022n/an/a

-US$217m

Jun 30 2022n/an/a

-US$205m

Mar 31 2022n/an/a

-US$214m

Dec 31 2021US$10mUS$793k

-US$168m

Sep 30 2021n/an/a

-US$192m

Jun 30 2021n/an/a

-US$262m

Mar 31 2021n/an/a

-US$260m

Dec 31 2020US$8mUS$768k

-US$282m

Sep 30 2020n/an/a

-US$268m

Jun 30 2020n/an/a

-US$225m

Mar 31 2020n/an/a

-US$238m

Dec 31 2019US$8mUS$744k

-US$235m

Sep 30 2019n/an/a

-US$248m

Jun 30 2019n/an/a

-US$268m

Mar 31 2019n/an/a

-US$276m

Dec 31 2018US$7mUS$720k

-US$245m

Sep 30 2018n/an/a

-US$249m

Jun 30 2018n/an/a

-US$252m

Mar 31 2018n/an/a

-US$256m

Dec 31 2017US$15mUS$700k

-US$289m

Sep 30 2017n/an/a

-US$299m

Jun 30 2017n/an/a

-US$306m

Mar 31 2017n/an/a

-US$309m

Dec 31 2016US$9mUS$676k

-US$271m

Compensation vs Market: Steve's total compensation ($USD14.03M) is above average for companies of similar size in the MX market ($USD1.61M).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.

CEO

Steve Davis (62 yo)

8.1yrs

Tenure

US$14,028,139

Compensation

Mr. Stephen R. Davis, also known as Steve, J. D., served as the Director at Heron Therapeutics Inc. since September 2019 until February 21, 2023. He has been the Chief Executive Officer of ACADIA Pharmaceu...

Leadership Team

NamePositionTenureCompensationOwnership
Stephen Davis
President8.1yrsUS$14.03m0.054%
MX$ 37.4m
Mark Schneyer
Executive VP & CFO2.1yrsUS$2.35m0.0096%
MX$ 6.6m
Brendan Teehan
Executive VP1.9yrsUS$2.30m0.015%
MX$ 10.2m
Austin Kim
Executive VP5.3yrsUS$4.70m0.028%
MX$ 19.3m
James Kihara
VP, Chief Accounting Officer & Corporate Controller3.2yrsno data0.0066%
MX$ 4.5m
Bob Mischler
Senior Vice President of Strategy & Technology Operationsno datano datano data
Mark Johnson
Vice President of Investor Relationsno datano datano data
Albert Kildani
Senior Vice President of Investor Relations & Corporate Communicationsless than a yearno datano data
Julie Fisher
Senior Vice President of Marketing & Commercial Strategy1.9yrsno datano data
Holly Valdiviez
Senior VP & Head of Sales1.8yrsno datano data
Rob Ackles
Senior VP & Chief People Officer1.8yrsno datano data
Ponni Subbiah
SVP, Global Head of Medical Affairs & Chief Medical Officer3.9yrsno datano data

2.0yrs

Average Tenure

54yo

Average Age

Experienced Management: ACAD *'s management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Stephen Davis
President8.1yrsUS$14.03m0.054%
MX$ 37.4m
Laura Brege
Independent Director15.4yrsUS$387.34k0.0083%
MX$ 5.7m
Julian Baker
Independent Director7.8yrsUS$372.34k0.063%
MX$ 43.2m
Paul Anderson
Member of the Scientific and Clinical Advisory Boardno datano datano data
Edmund Harrigan
Independent Director7.9yrsUS$382.34k0.012%
MX$ 8.0m
Daniel Soland
Independent Director8.6yrsUS$382.34k0.017%
MX$ 11.8m
Arvid Carlsson
Member of the Scientific and Clinical Advisory Boardno datano datano data
Carol Tamminga
Member of the Scientific and Clinical Advisory Boardno datano datano data
Herbert Meltzer
Member of the Scientific and Clinical Advisory Boardno datano datano data
James Daly
Independent Director7.8yrsUS$382.34k0.011%
MX$ 7.6m
Stephen Biggar
Independent Chairman of the Board10.8yrsUS$427.34k0.063%
MX$ 43.2m
Elizabeth Garofalo
Independent Director3.1yrsUS$372.34k0.011%
MX$ 7.9m

8.0yrs

Average Tenure

65yo

Average Age

Experienced Board: ACAD *'s board of directors are considered experienced (8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/11 20:30
End of Day Share Price 2023/07/14 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ACADIA Pharmaceuticals Inc. is covered by 37 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Ishan MajumdarBaptista Research
Esther Lannie HongBerenberg